Shorts
0:37
Eichenbaum Acorns Preview: Becoming a mentor
a month ago
by
Jayanth Sridhar, MD(+2 more)
0:48
Eichenbaum Acorns Preview: Impact of a podcast
a month ago
by
Jayanth Sridhar, MD(+2 more)
0:37
Eichenbaum Acorns Preview: Managing a retina podcast
a month ago
by
Jayanth Sridhar, MD(+2 more)
0:43
Eichenbaum Acorns Preview: Jayanth Sridhar, MD, on creating a podcast
a month ago
by
Jayanth Sridhar, MD(+2 more)
1:22
Celebrating National Women Physicians Day
2 months ago
by
Christina Y. Weng, MD, MBA, FASRS(+1 more)
0:37
Andreas Pollreisz, MD, encourages taking a second look with OCT-A
7 months ago
by
Andreas Pollreisz, MD(+1 more)
0:43
Sofia Androudi on retinal disorders mimicking inherited retinal diseases
7 months ago
by
Sofia Androudi, MD(+1 more)
0:43
Elon van Dijk on central serous chorioretinopathy
7 months ago
by
Elon van Dijk(+1 more)
0:50
Timothy Lai discusses the SALWEEN 1-year data
7 months ago
by
Timothy Lai(+2 more)
0:37
Giuseppe Querques, MD, PhD, sheds light on two challenging pathophysiologies at EURETINA
7 months ago
by
Giuseppe Querques, MD, PhD(+1 more)
0:49
Why the current staging for diabetic eye disease is obsolete
7 months ago
by
Stela Vujosevic, MD, PhD, FEBO(+2 more)
Advertisement
Advertisement
Trending on Modern Retina
1
First patient dosed in phase I/II trial of complement-targeting gene therapy for geographic atrophy
2
OLN324 shows comparable vision gains, potential durability advantage vs faricimab in phase 1b wAMD, DME study
3
Getting to the root of geographic atrophy: Diagnosis and management
4
FDA approves extended dosing intervals up to 20 weeks for EYLEA HD in wAMD and DME
5